SOURCE: Flamel Technologies

Flamel Technologies

May 22, 2015 08:30 ET

Flamel Technologies to Present at Jefferies 2015 Healthcare Conference

LYON, FRANCE--(Marketwired - May 22, 2015) - Flamel Technologies (NASDAQ: FLML) today announced that the Company will be presenting at the Jefferies 2015 Healthcare Conference to be held at the Grand Hyatt in New York City from June 1 - 4, 2015. Michael Anderson, Chief Executive Officer of Flamel, is scheduled to present on Monday, June 1st at 4:30 p.m. Eastern Time.

Mr. Anderson's presentation will be webcast live and can be accessed by visiting the Investor Relations section of the Company's website at A replay of the presentation will also be available and archived on the website for two weeks following the event.

About Flamel Technologies - Flamel Technologies SA (NASDAQ: FLML) is a specialty pharmaceutical company utilizing its core competencies in formulation development and drug delivery to develop safer and more efficacious pharmaceutical products, addressing unmet medical needs and/or reducing overall healthcare costs. Flamel currently has approvals for and markets two previously Unapproved Marketed Drugs ("UMDs") in the USA, Bloxiverz® (neostigmine methylsulfate injection) and Vazculep™ (phenylephrine hydrochloride injection). The Company intends to add to this branded business by creating additional products, focusing on the development of products utilizing Flamel's proprietary drug delivery platforms. Flamel currently has several products in development utilizing Micropump® (oral sustained release microparticles platform) along with its related technologies, LiquiTime® and Trigger Lock™. The lead project for Micropump is Sodium Oxybate. LiquiTime allows for the extended-release of liquid medicines (such as Ibuprofen and Guaifenesin) and Trigger Lock is an abuse-resistant iteration of Micropump, designed specifically for long-acting opioids. Additionally, the Company has developed a long acting injectable platform, Medusa™, a hydrogel depot technology currently being studied with Exenatide. Flamel's products are targeting high-value molecules and will utilize either the 505(b)(2) approval process for NDAs or biosimilar pathways ultimately approved by FDA and other regulatory authorities. The Company is headquartered in Lyon, France and has operations in St. Louis, Missouri, USA, and Dublin, Ireland. Additional information may be found at